influenza
acut
respiratori
diseas
caus
highli
infecti
influenza
virus
influenza
b
strong
capabl
spread
global
lead
advers
health
effect
respiratori
diseas
usual
caus
type
type
b
influenza
symptom
includ
headach
muscl
ach
cough
sudden
fever
infect
pandem
viru
emerg
initi
mexico
earli
becom
global
pandem
influenza
pandem
influenza
b
induc
coinfect
worldwid
therebi
caus
consider
panic
among
gener
popul
ion
channel
blocker
exampl
amantadin
rimantadin
neuraminidas
na
inhibitor
exampl
oseltamivir
zanamivir
peramivir
commonli
use
prevent
treatment
influenza
amantadin
rimantadin
howev
associ
neurolog
toxic
gastrointestin
side
effect
moreov
overus
medicin
found
result
drugresist
strain
variant
even
spread
countri
drug
use
infrequ
pandem
demonstr
resist
amantadin
rimantadin
previou
studi
suggest
clinic
isol
develop
amantadin
resist
respect
guangzhou
china
na
inhibitor
comparison
ion
channel
blocker
commonli
use
also
caus
respiratori
side
effect
even
death
exampl
oseltamivir
owe
intens
use
ii
higher
barrier
resist
overus
survey
show
low
level
resist
oseltamivir
survey
report
resist
resist
zanamivir
albeit
rare
report
among
immunodefici
patient
whether
antivir
agent
use
address
influenza
epidem
clear
furthermor
true
effect
oseltamivir
treatment
influenza
controversi
tradit
chines
herbal
medicin
tchm
richli
use
chines
clinic
wide
use
treat
prevent
respiratori
infect
diseas
unlik
western
medicin
tchm
differ
mechan
target
action
potenti
could
use
overcom
drug
resist
side
effect
therefor
export
new
antivir
medicin
tchm
new
choic
exampl
start
materi
shikim
acid
synthesi
oseltamivir
obtain
illicium
verum
type
tchm
roch
basel
switzerland
among
mani
type
tchm
banlangen
blg
thousandyear
histori
use
prevent
treatment
respiratori
tract
infect
particularli
respiratori
viral
diseas
blg
highlight
classic
antivir
antiinfluenza
agent
peopl
republ
china
pharmacopoeia
respect
addit
blg
one
eight
major
medicin
recommend
chines
govern
prevent
control
sever
acut
respiratori
syndrom
sar
sever
clinic
studi
evalu
efficaci
blg
granul
treatment
acut
pharyng
among
caus
virus
infect
upper
respiratori
tract
influenza
howev
none
studi
evidencebas
clinic
trial
isati
indigotica
root
iir
singl
largest
compon
blg
granul
previou
studi
suggest
isati
indigoticaroot
polysaccharid
irp
clemastanin
b
deriv
iir
inhibit
variou
subtyp
influenza
viru
vitro
inhibit
hemagglutinin
ha
viru
earli
stage
infect
import
antivir
mechan
iir
vivo
experi
reveal
clemastanin
b
significantli
inhibit
pneumonia
viru
prolifer
lung
tissu
zifeng
yang
zhengtu
li
unpublish
work
also
found
lignin
group
iir
isol
inhibit
nuclear
factorkappa
b
signal
activ
influenza
viru
block
export
np
protein
influenza
viru
articl
press
studi
also
shown
indirubin
also
contain
iir
deriv
antivir
antiinflammatori
effect
infect
due
influenza
viru
studi
suggest
blg
activ
ingredi
may
inhibit
influenza
viru
littl
concret
clinic
evid
provid
howev
efficaci
blg
treatment
season
influenza
wish
evalu
efficaci
safeti
blg
granul
treatment
season
influenza
evidencebas
clinic
trial
clinic
studi
random
doubleblind
doubl
control
trial
test
drug
placebo
noninferior
versu
posit
control
superior
versu
placebo
control
trial
conduct
patient
posit
test
influenza
viru
rapid
detect
antigen
influenza
viru
enrol
detect
nucleic
acid
influenza
viru
cultiv
influenza
viru
inconsist
patient
exclud
assign
randomli
three
group
equal
proport
group
oseltamivir
treatment
posit
control
blg
granul
treatment
test
group
placebo
group
patient
accept
treatment
observ
patient
followup
undertaken
day
tabl
figur
specif
item
collect
followup
period
outlin
tabl
differ
aspect
studi
activ
conduct
differ
site
instanc
patient
enrol
well
collect
specimen
data
conduct
outpati
depart
first
affili
hospit
guangzhou
medic
univers
biochem
examin
undertaken
laboratori
first
affili
hospit
guangzhou
medic
univers
viru
test
carri
clinic
virolog
divis
state
key
laboratori
respiratori
diseas
guangzhou
china
data
analys
done
southern
medic
univers
guangzhou
china
recommend
world
health
organ
influenzalik
ill
ili
use
basi
influenza
surveil
patient
present
acut
cough
fever
clinician
must
highli
vigil
test
infect
caus
influenza
viru
gener
rate
ili
case
lead
clinic
diagnosi
influenza
infect
approxim
higher
clinic
diagnos
exampl
acut
infect
upper
respiratori
tract
select
adult
ili
patient
inclus
studi
studi
design
enrol
case
specimen
collect
includ
pharyngealthroat
swab
blood
sampl
pharyngealthroat
secret
obtain
upper
respiratori
tract
patient
pharyngealthroat
swab
use
test
mrna
influenza
viru
viru
cultur
blood
sampl
use
test
viral
antibodi
personnel
particip
directli
studi
adequ
train
ensur
safeti
patient
blind
studi
design
data
qualiti
adher
studi
protocol
personnel
follow
guidelin
good
clinic
practic
gcp
follow
criteria
recruit
screen
enrol
reject
patient
patient
enrol
conform
inclus
criteria
howev
enrol
one
exclus
criteria
reject
criteria
termin
standard
furthermor
respons
particip
cooper
doctor
treatment
addit
cooper
followup
provid
us
inform
beyond
ethic
approv
inclus
criteria
patient
confirm
infect
influenza
influenza
b
viru
accord
realtim
polymeras
chain
reaction
pcr
viral
cultur
ii
age
year
axillari
temperatur
least
two
constitut
symptom
headach
chill
myalgia
fatigu
one
respiratori
symptom
cough
sore
throat
rhiniti
iii
ill
onset
within
h
iv
grant
written
inform
consent
exclus
criteria
detail
tabl
reject
criteria
meet
inclus
exclus
criteria
ii
withdraw
inform
consent
iii
receiv
followup
care
select
iv
seriou
violat
program
incorrect
administr
lead
effect
judg
termin
standard
refer
patient
meet
inclus
criteria
must
termin
trail
includ
final
statist
analys
termin
standard
detail
tabl
oseltamivir
treatment
group
receiv
one
oseltamivir
capsul
mgper
capsul
twice
day
minut
eat
taken
two
bag
analog
blg
granul
blg
group
receiv
two
bag
blg
granul
gper
bag
twice
day
dosag
set
accord
regul
china
food
drug
administr
minut
eat
taken
analog
oseltamivir
capsul
placebo
group
receiv
blg
analog
granul
twice
day
min
eat
taken
analog
oseltamivir
phosphat
capsul
blg
granul
blg
analog
granul
produc
accord
qualiti
requir
peopl
republ
china
pharmacopoeia
addit
file
furthermor
placebo
includ
white
powder
sugar
brown
powder
sugar
amylum
dextrin
caramel
syrup
lemon
yellow
drug
packag
hutchisom
whampoa
guangzhou
baiyunshan
chines
medicin
compani
limit
guangzhou
china
accord
requir
doubleblind
doublesimul
test
drug
use
doubleblind
trial
count
sort
third
parti
southern
medic
univers
china
drug
period
valid
treatment
particip
meet
standard
use
drug
axillari
temperatur
continu
hour
degrad
physic
cool
bodi
temperatur
gradual
rais
standard
met
symptom
treat
indic
fever
paracetamol
white
sputum
bromhexin
mild
asthmat
symptom
longterm
theophyllin
except
drug
use
furthermor
detail
inform
drug
use
regist
case
report
form
crf
first
primari
outcom
durat
ill
measur
hour
durat
ill
defin
time
symptom
onset
allevi
influenzalik
symptom
nasal
obstruct
run
nose
cough
sore
throat
headach
fatigu
myalgia
chill
sweat
definit
symptom
allevi
influenzalik
symptom
score
mild
mainten
stabl
symptom
h
anoth
primari
outcom
time
defervesc
measur
hour
time
first
dose
studi
medic
time
bodi
temperatur
decreas
defin
defervesc
sustain
h
defin
complet
defervesc
five
secondari
endpoint
consid
first
durat
viral
shed
endpoint
defin
time
ill
onset
first
time
viral
nucleic
acid
test
neg
second
endpoint
diseas
sever
assess
area
curv
auc
analysi
nine
influenzalik
symptom
score
auc
calcul
product
daili
symptom
score
multipli
durat
ill
third
endpoint
frequenc
acetaminophen
usag
fourth
endpoint
preval
secondari
influenza
complic
otiti
bronchiti
pneumonia
nasosinus
suppur
tonsil
acut
parot
rey
syndrom
central
nervou
system
diseas
myocard
pericard
acut
myositi
toxic
shock
syndrom
final
endpoint
econom
evalu
safeti
evalu
use
vital
sign
cardiopulmonari
sign
advers
reaction
electrocardiographi
clinic
laboratori
test
includ
liver
kidney
function
myocardium
enzym
indic
compar
drug
taken
advers
event
refer
advers
unintend
unplan
effect
vital
sign
symptom
diseas
laboratori
indic
chang
particip
enrol
clinic
trial
advers
event
necessarili
relat
drug
advers
event
divid
three
level
mild
moder
sever
tabl
causeandeffect
relationship
advers
event
studi
drug
evalu
accord
whether
agent
caus
death
ii
imperil
life
iii
lead
hospit
extend
durat
hospit
stay
iv
teratogen
caus
birth
defect
v
caus
perman
handicap
vi
carcinogen
tabl
seriou
advers
event
must
report
within
h
state
food
drug
administr
well
ethic
committe
manag
data
entri
analys
undertaken
specif
data
manag
respons
build
studi
databas
program
set
data
input
twice
confirm
two
keyboard
oper
receiv
special
train
verif
case
report
form
crf
identifi
input
error
correct
differ
databas
uncertainti
discuss
research
use
crf
question
form
question
form
shall
complet
research
within
specifi
time
limit
well
sign
date
complet
question
form
sent
depart
databas
manag
data
manag
revis
verifi
feedback
research
updat
databas
resend
form
necessari
confirm
verac
databas
via
blind
review
lock
data
correct
data
revis
lock
confirm
studi
promot
research
program
manag
statistician
data
manag
written
declar
correct
statist
analys
data
review
case
evalu
confirm
intenttotreat
popul
ittp
modifi
intenttotreat
popul
mittp
perprotocol
popul
ppp
safeti
analysi
popul
sap
decis
approv
data
manag
studi
promot
research
end
unblind
lock
databas
intentto
treat
popul
includ
patient
agre
enrol
studi
sign
inform
consent
form
modifi
intenttotreat
popul
includ
patient
use
test
drug
least
random
data
use
indic
efficaci
intervent
per
protocol
popul
includ
case
meet
inclus
criteria
full
accord
test
program
violat
protocol
slightli
complet
trial
complet
crf
pp
use
analyz
main
indic
evalu
efficaci
examin
consist
result
mitt
safeti
analysi
popul
data
demonstr
efficaci
intervent
patient
use
test
drug
least
random
studi
baselin
data
mitt
analys
main
indic
treatment
employ
pp
analys
conclus
mitt
analys
also
evalu
undertak
pp
analys
miss
data
last
observ
carri
forward
locf
approach
adopt
complet
dataset
laboratori
data
advers
event
side
effect
use
sa
analys
sap
denomin
preval
advers
reaction
softwar
use
statist
analys
spss
ibm
armonk
ny
usa
sa
sa
institut
cari
nc
usa
statist
infer
determin
use
twosid
test
p
consid
signific
confid
interv
use
efficaci
analys
use
locf
compens
case
fulli
cover
treatment
locf
approach
use
last
data
observ
transfer
databas
obtain
complet
dataset
safeti
assess
evalu
miss
data
comparison
dropout
rate
dropout
rate
caus
advers
event
undertaken
use
pearson
data
describ
mean
standard
deviat
confid
interv
necessari
minimum
maximum
median
valu
provid
pair
measur
data
also
show
differ
mean
standard
deviat
use
nonparametr
method
median
mean
valu
provid
count
data
describ
use
frequenc
distribut
correspond
percentag
data
concentr
describ
use
frequenc
distribut
correspond
percentag
well
median
averag
valu
qualit
inform
describ
use
posit
rate
number
posit
case
denomin
baselin
data
analys
two
set
includ
demograph
indic
well
gener
primari
secondari
indic
intervent
measur
data
describ
use
ttest
test
varianc
absent
count
data
describ
use
pearson
rate
data
describ
use
twosampl
wilcoxon
rank
sum
test
respect
analys
effect
quantit
variabl
comparison
group
undertaken
use
repeat
measur
analysi
varianc
covari
analysi
qualit
variabl
comparison
group
test
use
pearson
wherea
center
effect
analysi
use
cmh
rate
variabl
comparison
group
test
use
kruskalw
test
regress
analysi
center
effect
via
cmh
test
grade
logist
term
center
effect
analys
glm
method
use
quantit
indic
cmh
method
qualit
indic
rate
variabl
evalu
correct
use
logist
regress
model
regard
subgroup
analys
depend
circumst
factor
exclud
may
effect
prognosi
safeti
analys
preval
advers
event
two
group
compar
use
pearson
well
list
describ
event
occur
trial
descript
laboratori
test
result
test
describ
normalabnorm
chang
well
relationship
abnorm
chang
test
drug
chang
state
drug
use
clinic
trial
blg
granul
oseltamivir
approv
clinic
use
potenti
safeti
hazard
ensur
studi
patient
receiv
effect
treatment
rehabilit
placebo
control
group
provid
basic
drug
studi
commenc
explain
detail
research
purpos
method
process
satisfactori
answer
question
subject
obtain
written
inform
consent
includ
also
center
focu
purpos
applic
execut
studi
research
accept
research
plan
treatment
procedur
patient
research
schedul
crf
written
inform
consent
trial
clinic
unit
must
compli
gcp
scheme
clinic
trial
pharmaceut
supervisori
administr
depart
occasion
conduct
audit
inspect
cooper
sponsor
send
medic
examin
moder
seriou
advers
event
report
ethic
committe
treatment
effect
safeti
assur
patient
afford
key
factor
drug
includ
western
medicin
tchm
project
clinic
trial
provid
evid
whether
blg
granul
suitabl
safe
treat
prevent
season
influenza
blg
seem
display
clinic
effect
earli
onset
ill
previou
studi
show
ipr
clemastanin
b
lignin
separ
iir
antivir
role
earli
infect
stage
influenza
viru
accordingli
defin
time
ill
onset
hour
unfortun
criterion
made
patient
recruit
quit
difficult
howev
design
base
combin
tradit
medic
experi
modern
pharmacolog
studi
allow
us
discov
object
treatment
effect
blg
safeti
tchm
attract
major
attent
first
studi
blg
granul
use
day
acut
phase
may
safe
human
second
evalu
safeti
blg
base
chang
liver
kidney
function
treatment
addit
western
medicin
use
treat
influenza
oseltamivir
sell
rbmbox
china
expens
develop
countri
henc
need
explor
new
safe
inexpens
antiinfluenza
medicin
blg
sell
rbmbox
china
would
good
choic
furthermor
accord
basic
scienc
studi
activ
ingredi
iir
also
exert
immunemodul
antiinflamm
effect
vitro
vivo
polysaccharid
iir
promot
product
well
prolifer
lymphocyt
macrophag
mice
also
indirubin
deriv
suppress
express
sever
proinflammatori
cytokin
induc
influenza
infect
human
macrophag
alveolar
epitheli
cell
henc
evidencebas
clinic
trial
evalu
effect
blg
treat
inflamm
induc
influenza
infect
certainli
merit
summari
describ
first
clinic
trial
treatment
use
singl
herb
influenza
b
virus
china
hold
largescal
clinic
trial
comprehens
evalu
effect
safeti
blg
influenza
infect
base
result
pilot
studi
clinic
trial
review
ethic
committe
first
affili
hospit
guangzhou
medic
univers
end
first
patient
enrol
earli
june
patient
finish
treatment
observ
cycl
clinic
trial
expect
complet
end
